Fig. 6
From: Dual inhibition of glycolysis and glutaminolysis for synergistic therapy of rheumatoid arthritis
Treatment with c28MS decreases clinical scores and histologic scores in the K/BxN mouse model of arthritis. A Clinical scores were determined in vehicle-treated animals (n = 5) and c28MS-treated animals (n = 5) at a dose of 2.5 mg/kg. One hundred fifty microliters of K/BxN mouse serum was injected at day 0 and treatment was administered intraperitoneally daily from day 0 and continued until day 10. B Histologic scores were determined on day 10 after serum transfer in vehicle-treated or c28MS-treated mice. C Sections of the ankle joints of vehicle or c28MS-treated mice were stained with hematoxylin and eosin (H&E) or Safranin O on day 10 after arthritis induction. Black arrows indicate joint inflammation and hypertrophy, and yellow arrows highlight cartilage damage, which was reduced in c28MS-treated mouse ankles. D, E Induction of arthritis and treatment (c28MS and MTX) prognosis in treated and untreated K/BxN mice model (n = 5 per group) D clinical score and E paw swelling. Horizontal lines and error bars show the mean ± SD. * = p < 0.05; **** = p < 0.0001